Tergus Pharma competitors

Michael S. Weiss has served as the Company’s Executive Chairman, President and CEO since December 2011. Mr. Weiss is also currently a director of the Company. Mr. Weiss is a co-founder of, and has been a Managing Partner and Principal of Opus Point Partners since 2008. Mr. Weiss has also been the Executive Chairman, Strategic Development of Fortress Biotechnology since January 2014 and has served as Co-Vice Chairman of the Fortress Biotech Board of Directors since December 2013. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx and grew the company to close to a $1BB market capitalization company at its peak. While at Keryx, he raised over $150MM in equity capital through public and private offerings, executed a $100MM+ strategic alliance, negotiated multiple Special Protocol Assessments (“SPA”) agreements with the FDA and managed multiple large clinical trials.

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Anil D'souza is a Chief Executive Officer at TOLMAR and is based in Lincolnshire, Illinois. He has worked as President, Japan & Emerging Markets at HOSPIRA INC; First Lieutenant at Marine Corps Recruiting; and Client Manager at INTERNATIONAL BUSINESS MACHINES CORP. Anil attended Tuck School of Business at Dartmouth between 1998 and 2000, University of Chicago Committee on International Relations between 1989 and 1991, and University of Chicago between 1987 and 1991.

Cameron Reid is a Board Member at CHEMINOR DRUGS LIMITED and Chief Executive Officer at Interpharm Holdings Inc. He has worked as President at DR. REDDY'S LABORATORIES and Board Member at Interpharm Holdings Inc. Cameron works or has worked as Executive Vice President at Roussel NV. He studied at UCalgary and INSEAD.

David Seltzer is a Chairman/Pres/CEO/Treasurer at HI TECH PHARMACAL CO INC, Board Member at NovelStem International Corp, and Owner at Leading Pharma. He has experience at Bergen Brunswig Corp and AMERISOURCEBERGEN CORP and has worked as Exec VP:Admin/Treasurer/Secy at HI TECH PHARMACAL CO INC, Treasurer/Secretary at HI TECH PHARMACAL CO INC, and VP:Admin/COO/Treasurer/Secy at HI TECH PHARMACAL CO INC. David attended Queens University of Charlotte.

Ian Lennox is a CEO/Chairman at Olon Ricerca Bioscience LLC. He attended HBSc and MBA.